What is ArriVent BioPharma, Inc. (AVBP) stock price today?

ArriVent BioPharma, Inc. (AVBP) is currently trading at $16.73, up 0.12% today.

What is AVBP P/E ratio?

ArriVent BioPharma, Inc.'s P/E ratio is -7.60. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is AVBP return on equity (ROE)?

ArriVent BioPharma, Inc.'s return on equity (ROE) is -50.26%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is ArriVent BioPharma, Inc.'s market cap?

ArriVent BioPharma, Inc. has a market capitalization of $779.20M.

NASDAQ · Biotechnology

ArriVent BioPharma, Inc. (AVBP) Stock

$16.73 +0.12% NASDAQ: AVBP Healthcare

Valuation

Metric	Value
Price	$16.73
Market Cap	$779.20M
P/E Ratio	-7.60
P/B Ratio	3.63
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$35.83
52-Week Low	$13.21
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-50.26%
ROA	-41.48%
ROCE	-47.96%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	12.81

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-9.0M	$-37.0M	$-75.0M	$-94.0M	$-178.0M
Net Profit	$-52.0M	$-37.0M	$-69.0M	$-80.0M	$-166.0M
EPS	$-40.44	$-1.10	$-2.17	$-2.56	$-4.32
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$43.0M	$183.0M	$163.0M	$275.0M	$333.0M
Total Liabilities	$2.0M	$8.0M	$12.0M	$17.0M	$26.0M
Cash	$37.0M	$163.0M	$150.0M	$74.0M	$46.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight PR Newswire · Jun 15, 2026 The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight PR Newswire · Jun 1, 2026 ArriVent BioPharma Reports First Quarter 2026 Financial Results GlobeNewswire · May 11, 2026 A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate Simply Wall St. · May 10, 2026 ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers GlobeNewswire · May 7, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-13.0M	$-44.0M	$-56.0M	$-70.0M	$-161.0M
Investing Cash Flow	$-40.0M	$0	$0	$-192.0M	$-71.0M
Financing Cash Flow	$0	$0	$-2.0M	$1.0M	$0
Net Cash Flow	$37.0M	$126.0M	$-13.0M	$-76.0M	$-29.0M
Free Cash Flow	$-13.0M	$-44.0M	$-56.0M	$-70.0M	$-161.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-2.11
EV / EBITDA	-7.01
FCF Yield	-11.36%
Quick Ratio	14.16
Interest Coverage	0.00
Return 1Y	44.08%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held1.63%

Institutions Held96.03%

Institutions Float Held97.63%

Institutional Holder	Shares	Report Date
Suvretta Capital Management, LLC	4,401,083	2026-03-31
Infinitum Asset Management, LLC	4,148,923	2026-03-31
HHLR Advisors, LTD	3,929,117	2026-03-31
Orbimed Advisors LLC.	3,027,328	2026-03-31
FMR, LLC	3,016,132	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BDTXBlack Diamond Therapeutics, Inc.	$1.83	+1.10%	-2.62	$104.86M	0.00%
ERASErasca, Inc.	$16.03	+3.69%	-15.52	$5.56B	0.00%
EXELExelixis, Inc.	$59.86	+1.42%	17.78	$15.05B	0.00%
HCMHUTCHMED (China) Limited	$11.25	+0.99%	4.28	$1.96B	0.00%
IDYAIDEAYA Biosciences, Inc.	$36.11	+0.14%	-19.46	$3.43B	0.00%

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is led by CEO Zhengbin Yao, employs 52 people, headquartered in US, publicly traded since 2024.

ArriVent BioPharma, Inc. (AVBP) stock trades at $16.73 with a market capitalization of $779.20M. The stock is valued at a price-to-earnings (P/E) ratio of -7.60, price-to-book of 3.63, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $13.21 and $35.83, and currently trades 53.3% below its 52-week high.

On profitability, ArriVent BioPharma, Inc. generates a return on equity (ROE) of -50.26%, return on capital employed of -47.96%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides